Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs S&P Global Inc — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B), while S&P Global Inc trades at $403.72 (market cap $116.50B). The key difference: S&P Global Inc is far larger — about 51.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and S&P Global Inc pays a 0.98% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SLS | SPGI | |
|---|---|---|
Market Cap | $2.28B | $116.50B |
Volume | 3,128,960 | 1,430,714 |
Sector | Health | Financials |
52-Week High | $15.46 | $517.92 |
52-Week Low | $1.39 | $370.42 |
Enterprise Value | $2.15B | $127.99B |
Typical Hold Time | — | 123 Days |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
S&P Global (SPGI) trades at $402.73, up 1.67% with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock faces technical headwinds with bearish moving averages but maintains robust fundamentals including 30.5% net margins and consistent revenue growth from $15.3B to $16.1B projected for 2026. Recent developments include expansion into digital asset risk assessment and the acquisition of OpenZeppelin, positioning the company for AI-driven growth across its financial services divisions.
The outlook remains positive given S&P Global's dominant market position and margin expansion potential, though investors should monitor debt levels increasing to 23.3% of assets. Near-term catalysts include Q3 2026 earnings on October 27, with the stock offering 26% upside to analyst targets despite current technical weakness suggesting potential entry points near $391 support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
